In line with that, the percentage of T2D patients who reach an HbA1C target <7.0% progressively decrease with advancing anti-diabetic treatments, amounting to 88% and 36% in patients treated with metformin only or with a variety of antidiabetic drugs including insulin, respectively [27]. This evidence concerns the gene INS and type 2 diabetes mellitus.